Table 2:

Multivariable logistic regression model for cervical cancer screening within 2 years after stem cell transplant (SCT)

Variable	Allogeneic SCT (n=436)		Autologous SCT (n=1048)
	Odds ratio (95% CI)	p	Odds ratio (95% CI)	p
Cancer type
Leukemia	Ref.		Ref.
Lymphoma	0.55 (0.31–1.00)	0.05	0.73 (0.39–1.38)	0.33
Myeloma	0.78 (0.26–2.34)	0.66	0.72 (0.39–1.35)	0.31
Other	0.32 (0.11–0.92)	0.04	0.74 (0.37–1.50)	0.41
Year of SCT
1998–2001	Ref.		Ref.
2002–2005	0.94 (0.33–2.65)	0.90	1.28 (0.65–2.52)	0.48
2006–2009	1.00 (0.38–2.64)	0.99	1.20 (0.63–2.29)	0.59
2010–2013	1.28 (0.50–3.27)	0.60	1.24 (0.67–2.31)	0.50
Age group, yr
<30	0.42 (0.18–0.99)	0.05	0.86 (0.40–1.85)	0.70
30–40	Ref.		Ref.
41–50	1.07 (0.54–2.11)	0.84	0.79 (0.44–1.43)	0.43
51–60	0.64 (0.34–1.22)	0.18	0.48 (0.27–0.85)	0.01
61–65	0.45 (0.20–1.00)	0.05	0.32 (0.17–0.59)	<0.01
≥66	0.08 (0.02–0.38)	<0.01	0.07 (0.03–0.15)	<.001
Region
Northeast	Ref.		Ref.
North Central	0.88 (0.49–1.58)	0.67	0.87 (0.58–1.32)	0.52
South	1.25 (0.71–2.19)	0.45	0.89 (0.60–1.32)	0.56
West	0.67 (0.35–1.28)	0.23	0.96 (0.62–1.50)	0.86
Unknown	2.08 (0.46–9.44)	0.34	1.29 (0.57–2.96)	0.54
Insurance type
PPO	Ref.		Ref.
HMO	1.16 (0.61–2.19)	0.65	0.97 (0.67–1.42)	0.88
Other	1.39 (0.87–2.21)	0.17	0.96 (0.71–1.29)	0.77
Comorbiditya
None	Ref.		Ref.
Yes	1.11 (0.72–1.71)	0.64	0.77 (0.58–1.02)	0.06
GVHD
No	Ref.		--
Yes	0.50 (0.32–0.79)	<0.01

GVHD, graft vs. host disease; HMO, health maintenance organization; PPO, preferred provider organization.

^aComorbidity based on Deyo comorbidity index [reference 18: Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992 Jun;45(6):613–619].